Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function

Mantle Cell Lymphoma (MCL) is a non-Hodgkin lymphoma with a median survival rate of five years. Standard treatment with high-dose chemotherapy plus rituximab (anti-CD20 antibody) has extended overall survival although, the disease remains incurable. Histone deacetylases (HDAC) are a family of enzyme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical and biophysical research communications 2021-01, Vol.534, p.773-779
Hauptverfasser:	Watters, January M., Wright, Gabriela, Smith, Matthew A., Shah, Bijal, Wright, Kenneth L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibody dependent cellular cytotoxicity Antineoplastic Agents, Immunological - pharmacology Apoptosis Apoptosis - drug effects Apoptosis - genetics Cell Death - drug effects Cell Line, Tumor Cytotoxicity, Immunologic Histone deacetylase 8 Histone Deacetylase Inhibitors - pharmacology Histone Deacetylases - genetics Human natural killer cells Humans Hydroxamic Acids - pharmacology Indoles - pharmacology Interferon-gamma Interferon-gamma - metabolism Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - immunology Lymphoma, Mantle-Cell - pathology Mantle cell lymphoma Repressor Proteins - antagonists & inhibitors Repressor Proteins - genetics Rituximab - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!